Where does CTI Biopharma Corp. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CTI Biopharma Corp. ranks #31,327 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CTI Biopharma Corp. hold?

CTI Biopharma Corp. holds 8 US utility patents granted between 2015 and 2021, spanning 5 technology areas.

What is CTI Biopharma Corp.'s Innovation Score?

CTI Biopharma Corp. has an Innovation Score of 28.3 out of 100 (27th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CTI Biopharma Corp. focus on?

CTI Biopharma Corp.'s top technology area is C07D (Heterocyclic Compounds) with 7 patents, ranking #1,096 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is CTI Biopharma Corp.'s patent grant rate increasing or decreasing?

CTI Biopharma Corp.'s recent grant velocity is -86% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for CTI Biopharma Corp.'s patents?

CTI Biopharma Corp.'s patents average 21.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CTI Biopharma Corp. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CTI Biopharma Corp.

USPTO PatentsView assignee record - 8 granted patents across 5 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, CTI ranks #31,327 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 5 technology areas.

#31,327
of 49,997 US assignees by volume: 27th percentile
by Innovation Score (28.3/100): 21.3
avg claims per patent: -86%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31327 · US Corporation #31,327 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,327/49,997
PHOTO-FINISH Cryptowerk
CPC-NARROW C07D · 5 areas
INNOV-THIN 28.3/100
CLAIMS-DENSE 21.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -86% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cryptowerk Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How CTI’s 28.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (27%) Velocity 0.0 pts (0%) Breadth 7.9 pts (28%) Claim depth 12.8 pts (45%)

Qualcomm Incorporated · highest

85
D and M Asset… · near

28
CTI Biopharma · this assignee

28
True Fabrications · near

28
University of Genoa · near

28
Cellresearch PTE · near

28
3D Lighting… · lowest

7

What this shows CTI's Innovation Score is 28.3/100 (27th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for CTI?

Each dot is one of CTI’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). CTI’s own 21.3 claims/patent is ABOVE the 18.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

CTI vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where CTI's grants concentrate

CTI Biopharma Corp. is a focused PatentsView assignee: 5 CPC subclasses with 87.5% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2019. By volume, CTI sits between Cryptowerk Corp. and Cusic Inc..

Cryptowerk

8
Crysoptix K K

8
CSE

8
Cstone Pharmaceut…

8
Ctrl-labs

8
Cubic Tech

8
Curv Brands

8
Cusic

8
CTI Biopharma ◀

8

What this shows CTI holds 8 patents at rank #31,230, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CTI

By rank, the assignees closest to #31,230 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in CTI's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for CTI, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), CTI ranks #1,096 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (28 here).

University of Genoa 28 True Fabrications, Inc. 28 Cellresearch Corporation PTE. Ltd. 28 D and M Asset Management, LLC 28

CTI's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 27th percentile higher than 27% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

CTI Biopharma Corp. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	50.0%
2017	2	25.0%
2019	1	12.5%
2021	1	12.5%

Which technologies does CTI Biopharma Corp. patent most?

C07D - Heterocyclic Compounds 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07C - Acyclic OR Carbocyclic Compounds 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CTI Biopharma Corp.'s patent record in context - here's where to go next.

CTI Biopharma Corp.'s lead technology class is C07D (Heterocyclic Compounds), 87.5% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #31,327 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CTI Biopharma Corp. against Cryptowerk Corp., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.